IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH), being held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
